Use of genomic panels to determine risk of developing type 2 diabetes in the general population: a targeted evidence-based review.

ABSTRACT: This evidence review addresses whether type 2 diabetes genomic risk panels improve health outcomes (e.g., reduce rates of developing type 2 diabetes) in low- or high-risk adults; two clinical scenarios promulgated by commercial companies offering such testing. Evidence for the analytic validity of available genomic profiles was inadequate. Clinical validity ranged from inadequate to convincing for 30 variants identified on five type 2 diabetes genomic panels and by genome-wide association studies. Eight common variants were identified for general population use; evidence credibility based on published criteria was strong for two variants, moderate for two variants, and weak for four variants. TCF7L2 had the largest per-allele odds ratio of 1.39 (95% confidence interval 1.33-1.46). Models c

SUBMITTER: Palomaki GE 

PROVIDER: S-EPMC4684162 | biostudies-literature | 2013 Aug

REPOSITORIES: biostudies-literature